Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma

Abstract

The study met its primary end point, demonstrating activity of regorafenib in patients with progressive metastatic osteosarcoma. No new safety signals were observed. Regorafenib should be considered a treatment option for patients with relapsed metastatic osteosarcoma.